What is the fair value of Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) stock?

The current fair value estimate for Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) is $9.76. This implies an estimated downside of 9.8% versus the current market price.

Is Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 9.8% versus the current market price.

How is the financial health of Drugs Made In America Acquisition Corp Unit?

The current financial health read for Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

What is the P/E ratio for Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U)?

The current P/E ratio listed for Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) is 43.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Drugs Made In America Acquisition Corp Unit?

The current market capitalization listed for Drugs Made In America Acquisition Corp Unit is 263.2 M.

What is the enterprise value of Drugs Made In America Acquisition Corp Unit?

The current enterprise value listed for Drugs Made In America Acquisition Corp Unit is 263.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Drugs Made In America Acquisition Corp Unit?

The ticker symbol for Drugs Made In America Acquisition Corp Unit is NASDAQ-DMAA.U, and the stock is listed on NASDAQ.

What is the debt-to-total-capital ratio for Drugs Made In America Acquisition Corp Unit?

The current debt-to-total-capital ratio listed for Drugs Made In America Acquisition Corp Unit is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Drugs Made In America Acquisition Corp Unit?

The free float listed for Drugs Made In America Acquisition Corp Unit is 81.1%. Free float helps investors understand how much of the share base is available for public trading.

Drugs Made In America Acquisition Corp Unit (DMAAU) Fair Value &...

Q: Does Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U) pay dividends?

The latest available data indicates no current dividend yield for Drugs Made In America Acquisition Corp Unit (NASDAQ-DMAA.U).

Drugs Made In America Acquisition Corp Unit (DMAAU)

Drugs Made In America Acquisition Corp. Unit (DMAA.U) is a NASDAQ-listed debt/equity composite unit associated with Drugs Made In America Acquisition Corp., a special purpose acquisition company incorporated in 2024 and based in Fort Lauderdale, Florida. The company does not have significant operating activities and is organized to pursue a business combination, which may include a merger, share exchange, asset acquisition, share purchase, recapitalization, or reorganization with one or more businesses. As a unit security, DMAA.U represents a listed hybrid instrument rather than an operating company share.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	P/E Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-DMAA.U	$9.76	-9.8% Downside	Fair	Not available	Not available	Good	0.0%	43.2x	263.2 M	263.5 M	0.1%	81.1%	0.9	-8.5%